Eli Lilly Return on Tangible Equity 2012-2026 | LLY
Current and historical return on tangible equity values for Eli Lilly (LLY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Unlock Macrotrends Premium
Start 7-Day Free Trial
Eli Lilly Return On Tangible Equity Historical Data
Date
TTM Net Income
Tangible Equity
Return on Tangible Equity
2025-12-31
$20.64B
$9.09B
227.10%
2025-09-30
$18.41B
$6.14B
299.70%
2025-06-30
$13.80B
$3.77B
365.95%
2025-03-31
$11.11B
$2.41B
460.59%
2024-12-31
$10.59B
$1.69B
625.06%
2024-09-30
$8.37B
$0.87B
967.91%
2024-06-30
$7.34B
$0.47B
1559.02%
2024-03-31
$6.14B
$0.21B
2994.63%
2023-12-31
$5.24B
$-0.06B
-8698.76%
2023-09-30
$4.99B
$0.06B
8384.87%
2023-06-30
$6.50B
$-0.26B
-2470.72%
2023-03-31
$5.69B
$-0.99B
-576.15%
2022-12-31
$6.25B
$-1.50B
-416.68%
2022-09-30
$6.03B
$-1.98B
-304.71%
2022-06-30
$5.69B
$-2.72B
-209.09%
2022-03-31
$6.13B
$-3.34B
-183.43%
2021-12-31
$5.58B
$-4.08B
-136.80%
2021-09-30
$5.97B
$-4.82B
-123.89%
2021-06-30
$6.07B
$-5.45B
-111.47%
2021-03-31
$6.09B
$-5.94B
-102.65%
2020-12-31
$6.19B
$-6.81B
-91.01%
2020-09-30
$5.57B
$-7.36B
-75.75%
2020-06-30
$5.62B
$-7.53B
-74.65%
2020-03-31
$5.53B
$-7.62B
-72.59%
2019-12-31
$8.32B
$-7.52B
-110.63%
2019-09-30
$7.95B
$-3.50B
-226.99%
2019-06-30
$7.84B
$-0.21B
-3762.11%
2019-03-31
$6.26B
$2.56B
244.63%
2018-12-31
$3.23B
$6.11B
52.94%
2018-09-30
$0.45B
$4.80B
9.37%
2018-06-30
$-0.14B
$4.84B
-2.97%
2018-03-31
$1.12B
$5.30B
21.22%
2017-12-31
$-0.20B
$5.03B
-4.05%
2017-09-30
$2.23B
$5.65B
39.37%
2017-06-30
$2.45B
$5.81B
42.09%
2017-03-31
$2.19B
$5.94B
36.85%
2016-12-31
$2.74B
$6.16B
44.45%
2016-09-30
$2.44B
$6.10B
40.06%
2016-06-30
$2.47B
$6.00B
41.09%
2016-03-31
$2.32B
$6.01B
38.62%
2015-12-31
$2.41B
$5.99B
40.19%
2015-09-30
$2.36B
$7.30B
32.32%
2015-06-30
$2.06B
$8.89B
23.18%
2015-03-31
$2.19B
$10.76B
20.38%
2014-12-31
$2.39B
$12.79B
18.71%
2014-09-30
$2.69B
$13.43B
20.03%
2014-06-30
$3.39B
$13.31B
25.49%
2014-03-31
$3.86B
$12.66B
30.53%
2013-12-31
$4.68B
$11.70B
40.02%
2013-09-30
$4.78B
$10.88B
43.96%
2013-06-30
$4.91B
$10.53B
46.62%
2013-03-31
$4.63B
$10.14B
45.63%
2012-12-31
$4.09B
$9.94B
41.13%
2012-09-30
$4.12B
$9.54B
43.19%
2012-06-30
$4.03B
$9.24B
43.60%
2012-03-31
$4.30B
$9.28B
46.36%
2011-12-31
$4.35B
$9.19B
47.29%
2011-09-30
$4.66B
$8.99B
51.83%
2011-06-30
$4.73B
$8.55B
55.25%
2011-03-31
$4.88B
$7.77B
62.75%
2010-12-31
$5.07B
$7.08B
71.61%
2010-09-30
$4.82B
$6.64B
72.53%
2010-06-30
$4.45B
$6.16B
72.36%
2010-03-31
$4.26B
$5.80B
73.54%
2009-12-31
$4.33B
$5.16B
83.94%
2009-09-30
$-0.22B
$4.40B
-4.88%
2009-06-30
$-1.62B
$5.72B
-28.36%
2009-03-31
$-1.82B
$7.63B
-23.89%
2008-12-31
$-2.07B
$9.80B
-21.15%
2008-09-30
$2.41B
$11.86B
20.34%
2008-06-30
$3.80B
$11.62B
32.73%
2008-03-31
$3.51B
$10.79B
32.53%
2007-12-31
$2.95B
$9.93B
29.73%
2007-09-30
$2.23B
$9.88B
22.58%
2007-06-30
$2.18B
$10.52B
20.71%
2007-03-31
$2.34B
$11.24B
20.79%
2006-12-31
$2.66B
$11.88B
22.41%
2006-09-30
$3.23B
$11.87B
27.23%
2006-06-30
$3.15B
$11.45B
27.53%
2006-03-31
$2.08B
$11.04B
18.83%
2005-12-31
$1.98B
$11.01B
17.98%
2005-09-30
$1.28B
$11.04B
11.56%
2005-06-30
$1.24B
$11.02B
11.23%
2005-03-31
$2.15B
$11.08B
19.37%
2004-12-31
$1.81B
$10.82B
16.73%
2004-09-30
$2.56B
$10.53B
24.29%
2004-06-30
$2.52B
$10.08B
24.99%
2004-03-31
$2.55B
$9.62B
26.53%
2003-12-31
$2.56B
$9.17B
27.93%
2003-09-30
$2.55B
$8.79B
28.99%
2003-06-30
$2.52B
$8.49B
29.68%
2003-03-31
$2.49B
$8.25B
30.12%
2002-12-31
$2.71B
$8.00B
33.87%
2002-09-30
$2.55B
$7.70B
33.06%
2002-06-30
$2.43B
$7.48B
32.53%
2002-03-31
$2.60B
$7.23B
35.97%
2001-12-31
$2.78B
$6.96B
39.96%
2001-09-30
$2.97B
$6.69B
44.41%
2001-06-30
$3.18B
$6.34B
50.17%
2001-03-31
$3.02B
$6.00B
50.31%
2000-12-31
$3.06B
$5.74B
53.28%
2000-09-30
$3.08B
$5.45B
56.45%
2000-06-30
$3.03B
$5.15B
58.88%
2000-03-31
$2.94B
$4.88B
60.28%
1999-12-31
$2.72B
$4.68B
58.19%
1999-09-30
$2.50B
$4.18B
59.85%
1999-06-30
$2.29B
$3.75B
61.03%
1999-03-31
$2.20B
$3.45B
63.86%
1998-12-31
$2.10B
$3.08B
68.05%
1998-09-30
$1.99B
$3.13B
63.57%
1998-06-30
$1.93B
$3.09B
62.42%
1998-03-31
$-0.30B
$3.08B
-9.60%
1997-12-31
$-0.38B
$2.91B
-13.21%
1997-09-30
$-0.47B
$2.65B
-17.69%
1997-06-30
$-0.51B
$2.44B
-20.93%
1997-03-31
$1.57B
$2.11B
74.28%
1996-12-31
$1.52B
$1.90B
80.21%
1996-09-30
$1.49B
$1.71B
87.18%
1996-06-30
$2.31B
$1.58B
145.81%
1996-03-31
$2.29B
$1.54B
149.04%
1995-12-31
$2.29B
$1.47B
156.30%
1995-09-30
$2.24B
$1.37B
163.36%
1995-06-30
$1.33B
$2.23B
59.50%
1995-03-31
$1.35B
$3.02B
44.72%
1994-12-31
$1.29B
$3.79B
33.99%
1994-09-30
$0.47B
$4.59B
10.30%
1994-06-30
$0.45B
$4.62B
9.70%
1994-03-31
$0.45B
$4.66B
9.62%
1993-12-31
$0.48B
$4.72B
10.17%
1993-09-30
$1.32B
$4.79B
27.48%
1993-06-30
$0.75B
$4.67B
16.12%
1993-03-31
$0.75B
$4.69B
15.90%
1992-12-31
$0.71B
$4.70B
15.07%
1992-09-30
$0.71B
$4.73B
14.98%
1992-06-30
$1.28B
$4.70B
27.15%
1992-03-31
$1.25B
$4.55B
27.53%
1991-12-31
$1.32B
$4.40B
29.89%
1991-09-30
$1.26B
$4.02B
31.36%
1991-06-30
$1.22B
$3.67B
33.24%
1991-03-31
$1.18B
$3.43B
34.31%
1990-12-31
$1.13B
$3.28B
34.35%
1990-09-30
$1.10B
$3.36B
32.68%
1990-06-30
$1.05B
$3.41B
30.87%
1990-03-31
$1.00B
$3.32B
29.97%
1989-12-31
$0.94B
$3.15B
29.81%
1989-09-30
$0.89B
$3.03B
29.39%
1989-06-30
$0.85B
$2.94B
28.91%
1989-03-31
$0.81B
$2.86B
28.43%
1988-12-31
$0.76B
$2.82B
26.98%
1988-09-30
$0.72B
$2.78B
26.02%
1988-06-30
$0.70B
$2.70B
26.00%
1988-03-31
$0.67B
$2.62B
25.60%
1987-12-31
$0.64B
$2.54B
25.35%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $887.629B
$65.179B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
